Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.795 USD | -0.31% | +4.18% | +4.41% |
04-01 | JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating | MT |
03-27 | Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.41% | 438M | |
-2.47% | 88.14B | |
+1.45% | 40.44B | |
-16.33% | 32.24B | |
+51.96% | 24.39B | |
-14.03% | 15.59B | |
-39.40% | 12.3B | |
-7.87% | 12.18B | |
-13.39% | 12.14B | |
+5.17% | 8.87B |
- Stock Market
- Equities
- ANNX Stock
- News Annexon, Inc.
- Annexon : Starts Phase 2 Trial of Huntington's Disease Drug